[Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab. What repercussions will they have in clinical practice?].
Colozza
Mariantonietta
M
UO Oncologia Medica, Azienda Ospedaliera, Perugia.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use*; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000068878:Trastuzumab